Malignant Pleural Mesothelioma Market

Significant progress in understanding MPM pathophysiology has fueled the development of novel therapeutic strategies, including immunotherapies, gene therapies, and metabolic interventions. Companies such as AstraZeneca, Amphera BV, and PrECOG are advancing candidates through early- to mid-stage clinical development.

Volrustomig (MEDI5752) is a bispecific antibody targeting PD-1 and CTLA-4, designed to enhance anti-tumor immune activity while potentially minimizing toxicity. A Phase III trial is evaluating volrustomig in combination with carboplatin and pemetrexed in unresectable MPM, with outcomes expected after 2026.

Pegargiminase (ADI-PEG 20), an arginine-depleting enzyme therapy, is under evaluation in the Phase III ATOMIC-Meso trial. Positive survival data have prompted a rolling regulatory submission, with potential commercialization anticipated in 2025.

MesoPher, an autologous dendritic cell-based immunotherapy developed by Amphera BV, is currently in Phase III trials. Clinical results published in The Lancet Oncology (June 2024) demonstrated favorable immunogenicity and safety.

Other pipeline candidates include:

• Thiostrepton (RSO-021): RS Oncology
• Galinpepimut-S: Sellas Life Sciences Group
• CTX131: CRISPR Therapeutics AG
• VT3888: Vivace Therapeutics
• NUC-3373 (Fosifloxuridine Nafalbenamide): NuCana plc
• A2B694: A2 Biotherapeutics

The anticipated approval and launch of these therapies are expected to substantially reshape the malignant pleural mesothelioma treatment landscape.

To know more about malignant pleural mesothelioma clinical trials, visit @ Malignant Pleural Mesothelioma Treatment Drugs - https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Malignant Pleural Mesothelioma Market Dynamics

The malignant pleural mesothelioma market is shaped by complex clinical, regulatory, and legal dynamics. Many patients benefit from asbestos-related legal compensation, improving access to high-cost therapies. Additionally, several pipeline therapies have received Orphan Drug Designation (ODD), offering regulatory and commercial incentives.

Advances in biomarker development are also supporting earlier diagnosis and personalized treatment approaches. Therapies demonstrating superior efficacy over existing standards may command premium pricing in this high-unmet-need market.

However, market growth may be constrained by late-stage diagnosis, limited survival benefits of standard therapies, declining disease incidence in most 7MM regions, pricing pressures, reimbursement challenges, and healthcare workforce limitations. These factors underscore the importance of demonstrating meaningful clinical value and cost-effectiveness.